HAIRY CELL LEUKEMIA
Clinical trials for HAIRY CELL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new HAIRY CELL LEUKEMIA trials appear
Sign up with your email to follow new studies for HAIRY CELL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hairy cell leukemia: targeted drug combo enters trials
Disease control Recruiting nowThis study tests a new combination of drugs (tovorafenib and rituximab) for people with classical hairy cell leukemia, a rare blood cancer. The first part includes patients whose cancer returned or didn't respond to prior treatment; the second part compares the new combo to stand…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 06:49 UTC
-
New hope for rare leukemia patients who can't use standard targeted therapy
Disease control Recruiting nowThis study tests a drug called binimetinib in people with hairy cell leukemia that does not have the BRAF gene mutation. Standard treatments don't work for these patients. The drug targets a different gene (MEK) that is often active in this type of leukemia. About 40 adults will …
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 06:48 UTC
-
New hope for hairy cell leukemia: Chemo-Free combo tested
Disease control Recruiting nowThis study compares a new combination of non-chemotherapy drugs (vemurafenib plus obinutuzumab) against the standard chemotherapy combination (cladribine plus rituximab) for people with untreated hairy cell leukemia. The goal is to see which approach causes fewer side effects and…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 06:48 UTC
-
Promising combo may keep rare leukemia at bay
Disease control Recruiting nowThis study tests a two-step treatment for hairy cell leukemia, a rare blood cancer. First, patients receive cladribine chemotherapy to kill cancer cells, then rituximab immunotherapy to clear any remaining disease. The goal is to improve complete remission rates and reduce the ch…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Engineered immune cells take on Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage study tests whether a new type of immunotherapy, called anti-CD22 CAR T cells, is safe for people with hairy cell leukemia (classic or variant) that has come back or not responded to standard treatments. Up to 27 adults will have their own immune cells collected,…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New drug duo takes on tough leukemia
Disease control Recruiting nowThis study tests whether a combination of two pills, encorafenib and binimetinib, works better than the current drug vemurafenib for people with hairy cell leukemia that has a BRAF mutation and has not responded to or returned after treatment. About 45 adults will take the drugs …
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New pill takes on tough blood cancers in early human trial
Disease control Recruiting nowThis early-phase study tests an experimental oral drug called LP-168 in about 60 adults with several types of B-cell blood cancers (like lymphoma and leukemia) that have returned or not responded to prior treatments. The main goals are to find the safest dose and understand how t…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE1 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC